SML0005

Cerivastatin sodium salt hydrate

≥98% (HPLC), HMG-CoA reductase inhibitor, powder

• Synonym(e): (3R,5S,6E)-7-[4-(4-Fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-6-heptenoic acid sodium salt hydrate, Rivastatin hydrate
• Empirische Formel (Hill-System): C₂₆H₃₃FNNaO₅ · xH₂O
• CAS-Nummer: 143201-11-0
• Molekulargewicht: 481.53 (anhydrous basis)
• UNSPSC Code: 12352200
• PubChem Substance ID: 329825082
• NACRES: NA.77
• MDL number: MFCD20488047
• Assay: ≥98% (HPLC)
• Form: powder
• Storage condition: desiccated

Eigenschaften

• Produktname: Cerivastatin sodium salt hydrate, ≥98% (HPLC)
• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• optical activity: [α]/D +18 to +26° in ethanol
• storage condition: desiccated
• color: white to tan
• solubility: H₂O: ≥5 mg/mL
• originator: Bayer
• storage temp.: 2-8°C
• SMILES string: O.[Na+].COCc1c(nc(C(C)C)c(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)c1-c2ccc(F)cc2)C(C)C
• InChI: 1S/C26H34FNO5.Na.H2O/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4;;/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32);;1H2/q;+1;/p-1/b11-10+;;/t19-,20-;;/m1../s1
• InChI key: NJHMEKXCHXHQPP-PZLZTSNUSA-M

Beschreibung

General description

Cerivastatin sodium salt hydrate belongs to the statin class of lipid lowering agents. It helps in decreasing MAP kinase activation, blocking AP-1 (activator protein-1) and NF-kB (nuclear factor-kB ) binding activity, inhibiting inflammatory responses and ameliorated renal damage. It also lowers cholesterol. It is metabolized by cytochrome P450 (CYP)3A4 and (CYP)2C8. Cerivastatin sodium salt hydrate is linked to rhabdomyolysis.

Application

Cerivastatin sodium salt hydrate may be used in cell signaling studies.

Cerivastatin sodium salt hydrate has been used as a supplement in cell culture.

Biochem/physiol Actions

Cerivastatin sodium is an HMG-CoA reductase inhibitor. HMG-CoA is a key enzyme in the production of cholesterol.

HMG-CoA reductase inhibitor

Accumulated macrophages in atherosclerotic plaques result in plaque rupture and thrombus formation. Cerivastatin suppresses the growth of macrophages and decreases the expression of matrix metalloproteinases and tissue factor molecules, thus reduces acute coronary events.

Features and Benefits

This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Sicherheitshinweise

• Lagerklasse: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable